TCTR20161121002尚未招募未知
A Single Dose Crossover Fully Replicate Bioequivalence Study of Atorvastatin Calcium Equivalent to 80-mg Atorvastatin Tablets in Healthy, Adult, Human Subjects under Fasting Condition
Ranbaxy (Thailand) Co., Ltd.0 个研究点目标入组 40 人开始时间: 2016年11月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Male/Female must be 18-55 years of age, body mass index (BMI) =
- •18-25 kg/m2, inclusive.
- •2. Must be in good health as determined by medical history, vital signs, and physical examination.
- •3. Screening ECG without clinically significant abnormalities.
- •4. Screening visit Laboratory values of blood test including haematology(complete blood count (CBC) with differential), Fasting Blood Sugar(FBS), Blood Urea Nitrogen (BUN), Creatinine (Cr) analysis, Creatine phosphokinase (CPK) and liver function test (aspartate aminotransferase (AST)/alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, direct bilirubin, albumin, total protein) must be within the normal range or showing no clinically significant abnormalities in the opinion of clinical investigator.
- •5. Urinalysis results within normal limit or showing no clinically
- •significant abnormalities in the opinion of clinical investigator.
- •6. Must have negative results of serum hepatitis B surface antigen
- •(HbsAg), hepatitis C virus antibody (anti-HCV) and venereal disease research laboratory (VDRL).
- •7. Must have negative results of urine drug abuse testing of
- •methamphetamine, cannabinoids (Tetrahydrocannabinol), cocaine,
- •MDMA (3,4-methylenedioxy-methamphetamine), and opioids
- •(morphine and methadone)
- •8. Female subjects must have serum β-HCG negative.
- •9. Female subject who is childbearing potential agrees to use an
- •acceptable birth control method from visit 1 to the follow up visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device (IUD), and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow up visit. Hormonal contraceptives are not acceptable.
- •10. Female subject who is non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea)).
- •11. Female subjects must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at period I, II, III and period IV.
- •12. Non-smokers (never smoked or no smoking within the previous 2
- •13. Refrain from using herbal medications, dietary supplements (e.g., St.John’s Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of study drug (Day 1). Subjects must refrain from these items until the last collection time-point of period IV.
- •14. Subjects must have ended any medications at least 1 month prior to Day 1 and agree to continue their refraining throughout the follow up period.
- •15. Subjects must refrain from drinking caffeine and alcohol for at least 72 hours and one month, respectively prior to Day 1 and agree to continue their refraining throughout the last collection time-point of period IV.
- •16. Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by an Independent Ethic Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
排除标准
- •1. Known hypersensitivity to atorvastatin and its components.
- •2. Past medical history of renal and hepatic insufficiency.
- •3. Subject has a history of any illness that, in the opinion of the investigator, might confound the result of the study or pose an additional risk in administering study drug to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •4. Have history of drug abuse in the last 12 months.
- •5. Alcohol abuse or excessive use (in the opinion of the investigator, as judged by medical history) in the last 12 months.
- •6. Female subject is pregnant or breast feeding.
- •7. Donation or loss of whole blood:
- •a. ≥ 50 mL and ≤ 499 mL within 30 days prior to dosing
- •b. ≥ 500 mL within 56 days prior to dosing.
- •8. Participation in any investigation drug study within 1 month.
研究者
相似试验
尚未招募
1 期
SINGLE DOSE CROSSOVER FULLY REPLICATE BIOEQUIVALENCE STUDY OF ATORVASTATIN CALCIUM TABLETS 80 MG IN HEALTHY, ADULT, HUMAN SUBJECTS UNDER FASTING CONDITIOBioequivalence study in healthy volunteers.Bioequivalence,AtorvastatinTCTR20170109003Bio-innova and Synchron Co., Ltd.40
尚未招募
不适用
A Single Dose Two-Way Crossover Bioequivalence Study of Desloratadine Tablets (5 mg) in Normal, Healthy, Adult, Human Subjects under Fasting Conditioormal,Healthy,Adult,Human SubjectsTCTR20180202001Sun Pharmaceutical Industries Limited32
已完成
不适用
Pharmacodynamics end point study on Tetracosactide InjectioCTRI/2021/04/032482Sun Pharmaceutical Medicare Limited48
已完成
1 期
A study comparing the level of absorption of sildenafil from Sildenafil 100 mg Oral Films versus Viagra® 100 mg tablets and the effect of food on absorption of sildenafil from Sildenafil 100 mg Oral Films in healthy meErectile dysfunctionUrological and Genital DiseasesISRCTN13297409IBSA Institut Biochimique S.A.45
已完成
不适用
Bioequivalence study of Linagliptin 5 mg tablets in 24 healthy male under fasting conditionsIRCT20180620040164N4Alhavi pharmaceutical co.24